SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

AVE Avecho Biotechnology Limited

Healthcare · Biotechnology · website
$0.02
52wk 0.01 – 0.03
Overall
51.6
Value
62.5
Growth
40.6
Health
69.2
Quality
0.0
Momentum
79.6
Dividend
—
Price
About Avecho Biotechnology Limited

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

Price analytics

Returns

1 day 11.1%
1 week 0.0%
1 month -4.8%
3 months -13.0%
6 months 122.2%
1 year 233.3%
3 years 400.0%

Risk

Volatility (1y ann.) 123.8%
Beta vs ASX 200 0.45
Sharpe (1y) 1.54
VaR 95% (1-day) -10.0%
Max drawdown (1y) -33.3%
Off 1-year high -20.0%

Technicals

RSI(14) 47
vs 50DMA -2.8%
vs 200DMA 40.2%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 62.5
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
—
Price / Sales
0
Growth 40.6
Revenue growth (1y)
57
Revenue CAGR (3y)
24
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 79.6
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
36
Position in 52-week range
67

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$77.27M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
1.13
EV / EBITDA
-22.88
Price / Book
—
ROE
-268.2%
Operating margin
-3,145.0%
Net margin
0.0%
Total cash
$6.61M
Total debt
$227,545
Current ratio
5.38
Debt / Equity
0.12
Free cash flow
$-2.27M
Avg volume
4.97M
Latest annual results (FY ending 31 Dec 2025)
  • Revenue$1.25M
  • Gross profit$895.69K
  • Operating income-$6.00M
  • Net income-$4.42M
  • Diluted EPS-0.00
  • Free cash flow$1.10M
  • Net debt-$4.65M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4